Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: Meta-analysis of 5 trials-Reference-Cited by-同舟云学术

Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: Meta-analysis of 5 trials

Published:2014-08 Issue:2 Volume:61 Page:200-209
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Vierling John M.,Zeuzem Stefan,Poordad Fred,Bronowicki Jean-Pierre,Manns Michael P.,Bacon Bruce R.,Esteban Rafael,Flamm Steven L.,Kwo Paul Y.,Pedicone Lisa D.,Deng Weiping,Dutko Frank J.,DiNubile Mark J.,Koury Kenneth J.,Helmond Frans A.,Wahl Janice,Bruno Savino

Publisher

Elsevier BV

Subject

Hepatology

Reference17 articles.

1. How to optimize HCV therapy in genotype 1 patients with cirrhosis;Bourliere;Liver Int,2013

2. Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis;Bruno;J Hepatol,2013

3. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) – NCT01514890;Hezode;J Hepatol,2013

4. SVR12 rates and safety of triple therapy including teleprevir or boceprevir in 221 cirrhotic non responders treated in the French Early Access Program (ANRS CO20-CUPIC);Fontaine;J Hepatol,2013

5. Boceprevir for previously treated chronic HCV genotype 1 infection;Bacon;N Engl J Med,2011

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Direct-Acting Antiviral Agents for Hepatitis C Virus Infection—From Drug Discovery to Successful Implementation in Clinical Practice;Viruses;2022-06-17

2. Favorable Outcomes of Chinese HCV-Related Cirrhotic Patients with Sustained Virological Response after Pegylated Interferon Plus Ribavirin Treatment;BioMed Research International;2017

3. Network meta-analysis of first- and second-generation protease inhibitors for chronic hepatitis C genotype 1: efficacy based on RVR and SVR 24;European Journal of Clinical Pharmacology;2016-10-19

4. Cost-effectiveness of strategy-based approach to treatment of genotype 1 chronic hepatitis C;Journal of Gastroenterology and Hepatology;2016-09

5. Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development;Expert Opinion on Investigational Drugs;2016-03-21